Glaukos Co. (NYSE:GKOS) Given Consensus Rating of “Moderate Buy” by Brokerages

Glaukos Co. (NYSE:GKOS) has been assigned an average rating of “Moderate Buy” from the nine analysts that are covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $99.80.

GKOS has been the topic of several recent research reports. Stifel Nicolaus restated a “buy” rating and set a $110.00 target price on shares of Glaukos in a research report on Wednesday, April 3rd. StockNews.com cut Glaukos from a “hold” rating to a “sell” rating in a research note on Tuesday, February 27th. Needham & Company LLC raised their price objective on shares of Glaukos from $105.00 to $108.00 and gave the stock a “buy” rating in a report on Thursday, February 22nd. Citigroup raised their price objective on shares of Glaukos from $107.00 to $120.00 and gave the stock a “buy” rating in a report on Monday, March 25th. Finally, Wells Fargo & Company lifted their target price on shares of Glaukos from $83.00 to $103.00 and gave the company an “overweight” rating in a report on Thursday, February 22nd.

Glaukos Stock Down 1.8 %

GKOS stock opened at $95.15 on Friday. The stock’s 50 day simple moving average is $91.88 and its 200 day simple moving average is $80.55. Glaukos has a fifty-two week low of $45.38 and a fifty-two week high of $102.33. The company has a debt-to-equity ratio of 0.77, a quick ratio of 4.78 and a current ratio of 5.34. The company has a market cap of $4.71 billion, a P/E ratio of -34.23 and a beta of 1.08.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Wednesday, February 21st. The medical instruments supplier reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.07). The company had revenue of $82.40 million for the quarter, compared to the consensus estimate of $81.00 million. Glaukos had a negative return on equity of 22.67% and a negative net margin of 42.79%. The business’s revenue for the quarter was up 15.7% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.53) earnings per share. On average, research analysts expect that Glaukos will post -2.18 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Alex R. Thurman sold 434 shares of Glaukos stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $95.33, for a total transaction of $41,373.22. Following the transaction, the chief financial officer now owns 54,166 shares in the company, valued at approximately $5,163,644.78. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In related news, CFO Alex R. Thurman sold 434 shares of Glaukos stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $95.33, for a total transaction of $41,373.22. Following the transaction, the chief financial officer now owns 54,166 shares in the company, valued at approximately $5,163,644.78. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Mark J. Foley sold 4,560 shares of Glaukos stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $92.87, for a total transaction of $423,487.20. Following the transaction, the director now owns 33,220 shares in the company, valued at approximately $3,085,141.40. The disclosure for this sale can be found here. Insiders sold a total of 242,881 shares of company stock valued at $22,906,633 in the last 90 days. Company insiders own 7.80% of the company’s stock.

Institutional Trading of Glaukos

Hedge funds have recently bought and sold shares of the stock. Xponance Inc. raised its position in shares of Glaukos by 4.1% during the 4th quarter. Xponance Inc. now owns 2,879 shares of the medical instruments supplier’s stock valued at $229,000 after buying an additional 113 shares in the last quarter. Corient Private Wealth LLC grew its holdings in Glaukos by 0.7% during the 4th quarter. Corient Private Wealth LLC now owns 24,775 shares of the medical instruments supplier’s stock valued at $1,969,000 after purchasing an additional 163 shares during the last quarter. Profund Advisors LLC grew its holdings in Glaukos by 6.4% during the 4th quarter. Profund Advisors LLC now owns 2,879 shares of the medical instruments supplier’s stock valued at $229,000 after purchasing an additional 173 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in Glaukos by 4.8% during the 2nd quarter. PNC Financial Services Group Inc. now owns 4,353 shares of the medical instruments supplier’s stock valued at $310,000 after purchasing an additional 200 shares during the last quarter. Finally, American Century Companies Inc. grew its holdings in Glaukos by 3.1% during the 1st quarter. American Century Companies Inc. now owns 6,878 shares of the medical instruments supplier’s stock valued at $339,000 after purchasing an additional 207 shares during the last quarter. Hedge funds and other institutional investors own 99.04% of the company’s stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.